Interferon-β1a does not reduce expression of CCR5 and CXCR3 on circulating T cells

被引：10

作者：

Kivisäkk, P

Cotleur, AC

Lee, JC

Rudick, RA

Ransohoff, RM

机构：

[1] Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA

[2] Cleveland Clin Fdn, Dept Epidemiol & Biostat, Cleveland, OH 44195 USA

来源：

JOURNAL OF NEUROIMMUNOLOGY | 2003年 / 141卷 / 1-2期

关键词：

interferon-beta; 1a; CCR5; CXCR3;

D O I：

10.1016/S0165-5728(03)00247-9

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The expression of CCR5 and CXCR3, two chemokine receptors involved with homing of T cells to inflamed tissue, was examined longitudinally on CD4+ and CD8+ T cells in patients with a first demyelinating event of the central nervous system (CNS) randomized to receive i.m. injections of interferon-betala (IFN-beta1a) orplacebo. Blood for analysis was collected before and 48 h after injection at baseline and after 3 and 12 months of treatment. The results showed that treatment with IFN-beta1 a did not affect numbers of T cells expressing CCR5 and CXCR3 during the first 12 months of treatment, either at the peak of biological response or at the trough of interferon effect, at steady-state. (C) 2003 Elsevier B.V. All rights reserved.

引用

页码：150 / 154

页数：5

共 17 条

[1] CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions [J].

Balashov, KE ;

Rottman, JB ;

Weiner, HL ;

Hancock, WW .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (12) :6873-6878

[2]

DUQUETTE P, 1995, NEUROLOGY, V45, P1277

[3]

Francis G, 2001, NEUROLOGY, V56, P1628

[4] Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. [J].

Jacobs, LD ;

Beck, RW ;

Simon, JH ;

Kinkel, RP ;

Brownscheidle, CM ;

Murray, TJ ;

Simonian, NA ;

Slasor, PJ ;

Sandrock, AW .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (13) :898-904

[5] T-cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation:: implications for CNS trafficking [J].

Kivisäkk, P ;

Trebst, C ;

Liu, Z ;

Tucky, BH ;

Sorensen, TL ;

Rudick, RA ;

Mack, M ;

Ransohoff, RM .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2002, 129 (03) :510-518

[6] Expression of CCR2, CCR5, and CXCR3 by CD4+T cells is stable during a 2-year longitudinal study but varies widely between individuals [J].

Kivisäkk, P ;

Trebst, C ;

Lee, JC ;

Tucky, BH ;

Rudick, RA ;

Campbell, JJ ;

Ransohoff, RM .

JOURNAL OF NEUROVIROLOGY, 2003, 9 (03) :291-299

[7] Flow cytometric analysis of chemokine receptor expression on cerebrospinal fluid leukocytes [J].

Kivisäkk, P ;

Liu, ZG ;

Trebst, C ;

Tucky, B ;

Wu, LJ ;

Stine, J ;

Mack, M ;

Rudick, RA ;

Campbell, JJ ;

Ransohoff, RM .

METHODS, 2003, 29 (04) :319-325

[8] A controlled trial of natalizumab for relapsing multiple sclerosis. [J].

Miller, DH ;

Khan, OA ;

Sheremata, WA ;

Blumhardt, LD ;

Rice, GPA ;

Libonati, MA ;

Willmer-Hulme, AJ ;

Dalton, CM ;

Miszkiel, KA ;

O'Connor, PW .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (01) :15-23

[9] Lymphocyte traffic control by chemokines [J].

Moser, B ;

Loetscher, P .

NATURE IMMUNOLOGY, 2001, 2 (02) :123-128

[10] Cerebrospinal fluid abnormalities in a phase III trial of Avonex® (IFNβ-1a) for relapsing multiple sclerosis [J].

Rudick, RA ;

Cookfair, DL ;

Simonian, NA ;

Ransohoff, RM ;

Richert, JR ;

Jacobs, LD ;

Herndon, RM ;

Salazar, AM ;

Fischer, JS ;

Granger, CV ;

Goodkin, DE ;

Simon, JH ;

Bartoszak, DM ;

Bourdette, DN ;

Braiman, J ;

Brownscheidle, CM ;

Coats, ME ;

Cohan, SL ;

Dougherty, DS ;

Kinkel, RP ;

Mass, MK ;

Munchsauer, FE ;

O'Reilly, K ;

Priore, RL ;

Pullicino, PM ;

Scherokman, BJ ;

Wende, K ;

Weinstock-Guttman, B ;

Whitham, RH .

JOURNAL OF NEUROIMMUNOLOGY, 1999, 93 (1-2) :8-14

← 1 2 →